— Selective SIK2 inhibitors reduced disease activity in a mouse model of rheumatoid arthritis to levels comparable to approved therapies etanercept and upadacitinib — BOSTON, Mass. — November 5, 2026 — Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a computational drug discovery company developing breakthrough small molecule medicines through advanced structure-based design and AI-enabled chemistry, … Continue reading “Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in Rheumatoid Arthritis at ACR Convergence 2026” The post Nimbus Therapeutics to